OKYO Pharma Limited Notice of AGM (4020Y)
09 September 2020 - 4:00PM
UK Regulatory
TIDMOKYO
RNS Number : 4020Y
OKYO Pharma Limited
09 September 2020
OKYO Pharma Limited
("OKYO" or the "Company")
Notice of Annual General Meeting
OKYO Pharma Limited (LSE: OKYO), the life sciences and
biotechnology company focused on the discovery and development of
novel molecules to treat inflammatory dry eye diseases and chronic
pain, is pleased to announce that it will hold its annual general
meeting ("AGM") on 25 September 2020 at 10:00 a.m.
The Notice of AGM, together with a proxy form and the Annual
Report and Accounts for the year ended 31 March 2020, will be
posted to shareholders today. The Notice of AGM will shortly also
be available on the Company's website: www.okyopharma.com
Please note that arrangements for the AGM this year are
different from the usual public company in-person format. As we
expect significant restrictions on personal movement to still be in
place due to Covid-19, we are utilizing the provisions in our
recently adopted articles of association, which allow for the
holding of the meeting virtually, on an electronic platform.
Accordingly, this year's AGM will be an electronic meeting only.
All voting at the resolutions at the AGM will be conducted on a
poll (a requirement of our recently adopted articles of
association) which means that you should submit your proxy (by post
or, preferably, online voting) as soon as possible. We ask that,
where possible, questions which shareholders wish to raise be
submitted to info@okyopharma.com in advance.
The platform that we will be using will allow shareholders the
option to submit a separate poll card at the electronic meeting
but, to ease administration, we request that proxies be lodged in
advance wherever possible.
Full details of the operation and arrangements for the AGM are
set out in the Notice of AGM.
About OKYO Pharma Limited
OKYO Pharma Limited (LSE: OKYO) is a life sciences and
biotechnology company admitted to listing on the standard segment
of the Official List of the UK Financial Conduct Authority and to
trading on the Main Market for listed securities of the London
Stock Exchange plc. OKYO is focusing on the discovery and
development of novel molecules to treat inflammatory dry eye
diseases and chronic pain.
Enquiries:
OKYO Pharma Limited Willy Simon +44 (0)20 7495 2379
Optiva Securities Limited Robert Emmet + 44 (0)20 3981 4173
RedChip Companies Inc. Dave Gentry +1 407-491-4498
dave@redchip.com
For further information, please visit the Company's website at
www.okyopharma.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NOAFFFVFARITIII
(END) Dow Jones Newswires
September 09, 2020 02:00 ET (06:00 GMT)
Okyo Pharma (LSE:OKYO)
Historical Stock Chart
From Apr 2024 to May 2024
Okyo Pharma (LSE:OKYO)
Historical Stock Chart
From May 2023 to May 2024